Efficacy and safety of oral hormone combined with intrapleural injection of urokinase in the treatment of tuberculous pleurisy
口服激素联合胸腔注射尿激酶治疗结核性胸膜炎的疗效及安全性分析

摘要

目的 观察口服激素药物联合胸腔内注射尿激酶用药方案治疗结核性胸膜炎的临床价值。方法 选取92例结核性胸膜炎患者作为医学观察样本，收治时间2020年1月-2022年3月。按照随机原则分为对照组和观察组，每组各46例，对照组给予胸腔内注射尿激酶治疗，观察组采取口服激素与胸腔内注射尿激酶联合治疗方案，比较两组临床疗效，评价两种用药方案的安全性。结果 观察组总有效率为95.65%，对照组总有效率80.43%，两组间差异显著（P<0.05）。用药期间观察组出现1例轻微腹胀，发生率2.17%，两组均未出现皮疹、肝功能损伤、发热、胸腔出血及继发感染等不良反应病例。结论 治疗结核性胸膜炎时，采用口服激素与胸腔内注射尿激酶联合治疗方案的临床疗效显著，且安全性较高，患者获益较大，建议推广应用。

Abstract

Objective To observe the clinical value of oral hormone drugs combined with intrapleural injection of urokinase in the treatment of tuberculous pleurisy.
Methods: 92 patients with tuberculous pleurisy were selected as medical observation samples. The treatment time was from January 2020 to March 2022. According to the principle of randomization, they were divided into control group and observation group, with 46 cases in each group. The control group was treated with intrapleural injection of urokinase, and the observation group was treated with oral hormone and intrapleural injection of urokinase. The clinical efficacy of the two groups was compared and the safety of the two drug regimens was evaluated.
Results: the total effective rate was 95.65% in the observation group and 80.43% in the control group. There was significant difference between the two groups (p<0.05). During the treatment period, one case of slight abdominal distension occurred in the observation group, with an incidence of 2.17%. There were no adverse reactions such as skin rash, liver function injury, fever, thoracic hemorrhage and secondary infection in both groups.
Conclusion  : in the treatment of tuberculous pleurisy, the combination of oral hormone and intrapleural injection of urokinase has significant clinical efficacy, high safety and great benefit for patients. It is recommended to popularize it.